Kaling Cheung, MD
Pulmonary Disease · Walnut Creek
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 3
- Since medical school
- 36 years
- Graduated 1990
Offices
3 locations · Bass Medical Group · 292 clinicians in this group
Hospitals listed: John Muir Medical Center - Concord Campus · John Muir Medical Center - Walnut Creek Campus. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cheung’s office at (925) 932-6330 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence C51289 · Current
Licensed to practise in California · since 2003 · expires 2027-02-28 · Erasmus University of Rotterdam Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Critical Care Medicine
- American Board of Internal Medicine - Pulmonary Disease
- American Board of Internal Medicine - Sleep Medicine
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- John Muir Medical Center - Concord CampusConcord, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.235, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.675, Oct 2024 – Sep 2025
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
See every measure and the patient survey for John Muir Medical Center - Concord Campus
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.235 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.675 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.11 (0.21 to 2) · 1,612 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.77 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 184.13 (136.65 to 231.6) · 86 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.2 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 537 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 434 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,208 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.13 to 0.51) · 7,626 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.1 (1.29 to 4.91) · 2,723 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.21 (0 to 2.51) · 1,208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3 (1.7 to 4.3) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (3.24 to 12.3) · 1,216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.43 (0.43 to 6.43) · 1,253 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.93 (0.47 to 3.4) · 388 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.14 (0.58 to 1.69) · 6,288 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 263 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.636 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.254 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.904 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 312 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 768 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -6.8 · 295 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.1 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.1 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 504 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.1 to 8.8) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.9 (10.5 to 15.7) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 8.8 · 154 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.7 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.2) · 546 cases | No different | Jan 2024 – Dec 2024 |
What patients said (521 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$221,199
Medicare paid this office $221,199 for 576 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 324 | $89,924 | $168 |
| Sleep study in sleep lab (6 years or older) | 84 | $59,402 | $691 |
| New patient visit (60+ min) | 100 | $20,885 | $209 |
| Return visit (30+ min) | 127 | $16,872 | $107 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 12 | $8,751 | $729 |
See all 15 services
| Long return visit (40+ min) | 324 | $89,924 | $168 |
| Sleep study in sleep lab (6 years or older) | 84 | $59,402 | $691 |
| New patient visit (60+ min) | 100 | $20,885 | $209 |
| Return visit (30+ min) | 127 | $16,872 | $107 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 12 | $8,751 | $729 |
| New patient visit (45+ min) | 39 | $5,337 | $137 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 216 | $4,444 | $15 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 49 | $4,254 | $87 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 95 | $3,416 | $30 |
| Sleep study including heart rate, breathing, and sleep time | 19 | $2,543 | $134 |
| Test to determine lung volumes using sensors | 128 | $1,404 | $11 |
| Test to examine how well the lungs exchange gases | 127 | $1,036 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 97 | $891 | $9 |
| Test for exercise-induced lung stress | 40 | $835 | $20 |
| Test to measure expiratory airflow and volume | 38 | $286 | $7 |
Who their Medicare patients are
576 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 12% · Women 51% · Also on Medicaid 5% · Health risk score 1.24. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 72% · Chronic kidney disease 26% · Coronary heart disease 25% · Diabetes 24% · COPD 24% · Atrial fibrillation 23% · Depression 21% · Cancer 19% · Heart failure 15% · Stroke 8% · Dementia 4%.
The office billed $851,887, Medicare allowed $288,960 and paid $221,199; for 1,865 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 576 | 1,865 | 75 | 1.24 | $851,887 | $221,199 |
| 2023 | 611 | 1,741 | 76 | 1.31 | $1,037,716 | $249,144 |
| 2022 | 541 | 1,627 | 75 | 1.30 | $986,175 | $233,040 |
| 2021 | 453 | 1,241 | 75 | 1.42 | $725,833 | $185,965 |
| 2020 | 411 | 1,160 | 75 | 1.28 | $512,880 | $128,022 |
| 2019 | 509 | 1,503 | 76 | 2.07 | $571,348 | $146,266 |
| 2018 | 547 | 1,463 | 77 | 2.21 | $539,552 | $136,993 |
| 2017 | 580 | 1,604 | 76 | 1.89 | $574,290 | $141,495 |
| 2016 | 495 | 1,536 | 75 | 1.97 | $544,774 | $124,767 |
| 2015 | 478 | 1,468 | 75 | 1.86 | $411,216 | $122,636 |
| 2014 | 357 | 1,164 | 75 | 1.95 | $250,029 | $89,385 |
| 2013 | 323 | 1,170 | 75 | 1.97 | $252,607 | $93,303 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Long return visit (40+ min) | 288 | $90,517 | $160 |
| Sleep study in sleep lab (6 years or older) | 97 | $63,710 | $650 |
| Return visit (30+ min) | 178 | $27,838 | $113 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 26 | $17,732 | $682 |
| New patient visit (60+ min) | 79 | $15,151 | $192 |
| New patient visit (45+ min) | 61 | $8,380 | $137 |
| Critical care, first 30-74 minutes | 25 | $8,157 | $190 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 45 | $4,016 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,806 | $104 |
| Sleep study including heart rate, breathing, and sleep time | 13 | $2,054 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,800 | $67 |
| Test to determine lung volumes using sensors | 115 | $1,230 | $10 |
| Test for exercise-induced lung stress | 58 | $1,225 | $19 |
| Test to examine how well the lungs exchange gases | 123 | $981 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 93 | $845 | $9 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | $612 | $29 |
| Test to measure expiratory airflow and volume | 34 | $230 | $6 |
2022: 17 services
| Long return visit (40+ min) | 239 | $73,189 | $160 |
| Sleep study in sleep lab (6 years or older) | 97 | $64,100 | $635 |
| Return visit (30+ min) | 200 | $29,081 | $111 |
| New patient visit (60+ min) | 101 | $19,074 | $189 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 26 | $17,251 | $664 |
| Critical care, first 30-74 minutes | 25 | $8,029 | $187 |
| New patient visit (45+ min) | 54 | $7,221 | $134 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $2,754 | $92 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 15 | $1,555 | $97 |
| Test for exercise-induced lung stress | 55 | $1,108 | $20 |
| Test to examine how well the lungs exchange gases | 122 | $972 | $8 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $954 | $64 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 93 | $839 | $9 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | $765 | $29 |
| Test to determine lung volumes using sensors | 64 | $695 | $11 |
| Test to determine lung volumes using gas dilution or washout | 54 | $577 | $10 |
| Test to measure expiratory airflow and volume | 30 | $230 | $7 |
2021: 17 services
| Long return visit (40+ min) | 182 | $48,465 | $169 |
| Sleep study in sleep lab (6 years or older) | 69 | $47,300 | $657 |
| Return visit (30+ min) | 179 | $26,756 | $116 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 30 | $20,582 | $686 |
| New patient visit (60+ min) | 83 | $17,010 | $205 |
| New patient visit (45+ min) | 57 | $7,606 | $133 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $2,982 | $103 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 18 | $2,929 | $163 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $2,217 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,372 | $69 |
| Test to examine how well the lungs exchange gases | 99 | $828 | $8 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | $766 | $31 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 71 | $669 | $9 |
| Test to determine lung volumes using sensors | 51 | $566 | $11 |
| Test to determine lung volumes using gas dilution or washout | 47 | $533 | $11 |
| Test for exercise-induced lung stress | 16 | $350 | $21 |
| Test to measure expiratory airflow and volume | 30 | $235 | $7 |
2020: 19 services
| Long return visit (40+ min) | 151 | $35,651 | $135 |
| Return visit (30+ min) | 194 | $25,229 | $96 |
| Sleep study in sleep lab (6 years or older) | 26 | $18,321 | $632 |
| New patient visit (45+ min) | 82 | $10,498 | $128 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 15 | $9,817 | $654 |
| New patient visit (60+ min) | 41 | $7,215 | $176 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 25 | $5,623 | $216 |
| Telephone medical discussion with physician, 21-30 minutes | 27 | $2,946 | $105 |
| Extended patient service without direct patient contact, first hour | 20 | $2,171 | $103 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,952 | $115 |
| Extended office or other outpatient service, first hour | 12 | $1,453 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,018 | $73 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 76 | $860 | $11 |
| Test to examine how well the lungs exchange gases | 98 | $771 | $8 |
| Short return visit (20+ min) | 11 | $766 | $70 |
| Test to determine lung volumes using gas dilution or washout | 52 | $559 | $11 |
| Test to determine lung volumes using sensors | 47 | $491 | $10 |
| Test for exercise-induced lung stress | 11 | $210 | $19 |
| Test to measure expiratory airflow and volume | 19 | $140 | $7 |
2019: 15 services
| Critical care, first 30-74 minutes | 68 | $29,809 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 117 | $25,025 | $89 |
| Return visit (30+ min) | 167 | $20,460 | $93 |
| Long return visit (40+ min) | 99 | $20,386 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 97 | $13,021 | $64 |
| Sleep study in sleep lab (6 years or older) | 12 | $7,663 | $403 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,042 | $173 |
| New patient visit (45+ min) | 34 | $5,179 | $152 |
| New patient visit (60+ min) | 11 | $2,054 | $187 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 68 | $750 | $11 |
| Test to examine how well the lungs exchange gases | 90 | $698 | $8 |
| Test to determine lung volumes using sensors | 56 | $594 | $10 |
| Test to determine lung volumes using gas dilution or washout | 33 | $351 | $11 |
| Test for exercise-induced lung stress | 16 | $320 | $20 |
| Test to measure expiratory airflow and volume | 12 | $92 | $7 |
2018: 12 services
| Critical care, first 30-74 minutes | 94 | $33,512 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 130 | $27,803 | $92 |
| Long return visit (40+ min) | 129 | $23,230 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 135 | $18,338 | $63 |
| Return visit (30+ min) | 133 | $14,696 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $8,562 | $175 |
| New patient visit (45+ min) | 11 | $1,466 | $133 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 49 | $502 | $10 |
| Test to examine how well the lungs exchange gases | 65 | $486 | $7 |
| Test to determine lung volumes using sensors | 36 | $341 | $9 |
| Test to determine lung volumes using gas dilution or washout | 28 | $308 | $11 |
| Test to measure expiratory airflow and volume | 12 | $83 | $6 |
2017: 15 services
| Critical care, first 30-74 minutes | 83 | $30,240 | $188 |
| Long return visit (40+ min) | 133 | $23,696 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 117 | $22,361 | $89 |
| Return visit (30+ min) | 174 | $21,212 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 133 | $16,622 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,688 | $167 |
| New patient visit (45+ min) | 29 | $3,926 | $135 |
| New patient visit (60+ min) | 17 | $3,003 | $177 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,068 | $103 |
| Test for exercise-induced heart and lung stress | 17 | $1,035 | $61 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 61 | $691 | $11 |
| Test to examine how well the lungs exchange gases | 83 | $669 | $8 |
| Test to determine lung volumes using sensors | 48 | $521 | $10 |
| Test to determine lung volumes using gas dilution or washout | 34 | $380 | $11 |
| Test to measure expiratory airflow and volume | 14 | $96 | $6 |
2016: 17 services
| Return visit (30+ min) | 217 | $28,713 | $86 |
| Long return visit (40+ min) | 113 | $21,898 | $123 |
| Critical care, first 30-74 minutes | 48 | $16,565 | $180 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 22 | $12,237 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $9,570 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 77 | $8,054 | $60 |
| New patient visit (45+ min) | 54 | $7,142 | $132 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 16 | $5,403 | $60 |
| New patient visit (60+ min) | 20 | $3,632 | $182 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,344 | $117 |
| Test for exercise-induced heart and lung stress | 28 | $1,681 | $58 |
| Test to examine how well the lungs exchange gases | 94 | $688 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 60 | $613 | $10 |
| Test to determine lung volumes using gas dilution or washout | 47 | $474 | $10 |
| Test to determine lung volumes using sensors | 46 | $463 | $10 |
| Test to measure lung airway sensitivity | 11 | $275 | $25 |
| Test to measure expiratory airflow and volume | 11 | $80 | $7 |
2015: 17 services
| Return visit (30+ min) | 214 | $30,256 | $93 |
| Subsequent nursing facility care with moderate level of medical decision making, per day at least 30 minutes | 30 | $15,747 | $80 |
| Long return visit (40+ min) | 87 | $15,286 | $127 |
| Critical care, first 30-74 minutes | 34 | $9,983 | $188 |
| New patient visit (60+ min) | 56 | $9,665 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 73 | $9,053 | $62 |
| New patient visit (45+ min) | 59 | $8,348 | $141 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 26 | $8,136 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $6,251 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,599 | $173 |
| Test for exercise-induced heart and lung stress | 12 | $781 | $60 |
| Short return visit (20+ min) | 15 | $718 | $48 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 63 | $691 | $11 |
| Test to examine how well the lungs exchange gases | 72 | $546 | $8 |
| Test to determine lung volumes using sensors | 36 | $374 | $10 |
| Test to determine lung volumes using gas dilution or washout | 37 | $374 | $10 |
| Test to measure lung airway sensitivity | 11 | $249 | $23 |
2014: 13 services
| Return visit (30+ min) | 181 | $23,391 | $91 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 20 | $8,849 | $60 |
| Critical care, first 30-74 minutes | 24 | $8,709 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $8,389 | $89 |
| Short return visit (20+ min) | 89 | $7,507 | $64 |
| New patient visit (45+ min) | 50 | $7,229 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $6,994 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,388 | $174 |
| Long return visit (40+ min) | 23 | $3,195 | $128 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day at least 10 minutes | 14 | $2,812 | $39 |
| Test to determine lung volumes using sensors | 40 | $428 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | $397 | $11 |
| Test to examine how well the lungs exchange gases | 45 | $356 | $8 |
2013: 13 services
| Return visit (30+ min) | 151 | $25,123 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 93 | $14,211 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $9,660 | $87 |
| Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more | 17 | $8,061 | $59 |
| Critical care, first 30-74 minutes | 25 | $7,970 | $185 |
| Long return visit (40+ min) | 36 | $7,253 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,949 | $170 |
| New patient visit (45+ min) | 34 | $4,486 | $132 |
| Short return visit (20+ min) | 23 | $1,532 | $61 |
| Test for exercise-induced heart and lung stress | 21 | $1,231 | $59 |
| Test to determine lung volumes using sensors | 34 | $405 | $11 |
| Test to examine how well the lungs exchange gases | 43 | $363 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 25 | $280 | $11 |
Medicaid work
$3,104 in 2024
Medicaid paid $3,104 for 15 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 15 | $3,104 |
| 2024 | 15 | 1 | 15 | $3,104 |
Drugs they prescribed that Part D paid
$570,130
Pharmacies billed $570,130 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 847) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
371 generic and 476 brand-name prescriptions · $570,130 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ofev | 18 | $235,697 | $13,094 |
| Trelegy Ellipta | 105 | $114,016 | $1,086 |
| Breztri Aerosphere | 57 | $55,316 | $970 |
| Breo Ellipta | 41 | $28,639 | $699 |
| Stiolto Respimat | 38 | $23,951 | $630 |
See all 24 drugs
| Ofev | 18 | $235,697 | $13,094 |
| Trelegy Ellipta | 105 | $114,016 | $1,086 |
| Breztri Aerosphere | 57 | $55,316 | $970 |
| Breo Ellipta | 41 | $28,639 | $699 |
| Stiolto Respimat | 38 | $23,951 | $630 |
| Spiriva Respimat | 16 | $15,548 | $972 |
| Incruse Ellipta | 29 | $12,105 | $417 |
| Belsomra | 19 | $9,899 | $521 |
| Arnuity Ellipta | 21 | $9,352 | $445 |
| Advair Hfa | 14 | $8,307 | $593 |
| Anoro Ellipta | 13 | $6,253 | $481 |
| Bevespi Aerosphere | 11 | $3,725 | $339 |
| Fluticasone Propionate Hfa | 11 | $2,518 | $229 |
| Modafinil | 26 | $2,230 | $86 |
| Wixela Inhub | 17 | $1,929 | $113 |
| Azelastine | 31 | $1,255 | $40 |
| Albuterol Sulfate Hfa | 29 | $1,017 | $35 |
| Montelukast | 63 | $593 | $9 |
| Zolpidem | 35 | $266 | $8 |
| Clonazepam | 28 | $183 | $7 |
| Ropinirole | 12 | $167 | $14 |
| Amitriptyline | 13 | $133 | $10 |
| Trazodone | 17 | $103 | $6 |
| Gabapentin | 15 | $75 | $5 |
Year by year
| 2024 | 847 | 171 | 0% (0) | 56% | $570,130 |
| 2023 | 806 | 174 | 0% (0) | 59% | $430,624 |
| 2022 | 746 | 170 | None | 59% | $545,130 |
| 2021 | 790 | 170 | 0% (0) | 58% | $602,748 |
| 2020 | 701 | 152 | 0% (0) | 64% | $527,141 |
| 2019 | 463 | 98 | 0% (0) | 60% | $372,356 |
| 2018 | 473 | 80 | 5% (25) | 57% | $270,750 |
| 2017 | 569 | 111 | 3% (17) | 54% | $283,770 |
| 2016 | 753 | 137 | 3% (24) | 54% | $296,979 |
| 2015 | 726 | 114 | 6% (46) | 62% | $460,464 |
| 2014 | 606 | 91 | 4% (24) | 61% | $284,274 |
| 2013 | 479 | 80 | None | 58% | $130,563 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Trelegy Ellipta | 98 | $120,999 | $1,235 |
| Breztri Aerosphere | 66 | $52,927 | $802 |
| Breo Ellipta | 69 | $47,897 | $694 |
| Stiolto Respimat | 34 | $23,616 | $695 |
| Advair Hfa | 26 | $22,199 | $854 |
| Spiriva Respimat | 23 | $17,283 | $751 |
| Pirfenidone | 12 | $15,634 | $1,303 |
| Anoro Ellipta | 21 | $14,502 | $691 |
| Belsomra | 18 | $12,703 | $706 |
| Incruse Ellipta | 15 | $8,098 | $540 |
| Arnuity Ellipta | 18 | $6,622 | $368 |
| Ventolin Hfa | 11 | $1,534 | $139 |
| Montelukast | 66 | $1,104 | $17 |
| Azelastine | 17 | $930 | $55 |
| Albuterol Sulfate Hfa | 15 | $696 | $46 |
| Fluticasone Propionate | 11 | $388 | $35 |
| Clonazepam | 35 | $309 | $9 |
| Zolpidem | 26 | $183 | $7 |
| Gabapentin | 19 | $137 | $7 |
| Trazodone | 20 | $131 | $7 |
| Amitriptyline | 11 | $74 | $7 |
2022: 22 drugs
| Trelegy Ellipta | 69 | $83,251 | $1,207 |
| Breo Ellipta | 85 | $49,867 | $587 |
| Breztri Aerosphere | 41 | $31,180 | $760 |
| Stiolto Respimat | 31 | $29,602 | $955 |
| Spiriva Respimat | 27 | $22,640 | $839 |
| Advair Hfa | 19 | $17,623 | $928 |
| Symbicort | 22 | $11,702 | $532 |
| Anoro Ellipta | 12 | $10,888 | $907 |
| Belsomra | 16 | $10,374 | $648 |
| Arnuity Ellipta | 26 | $9,461 | $364 |
| Incruse Ellipta | 17 | $8,989 | $529 |
| Wixela Inhub | 16 | $8,853 | $553 |
| Azelastine | 23 | $1,849 | $80 |
| Albuterol Sulfate Hfa | 20 | $1,599 | $80 |
| Montelukast | 39 | $938 | $24 |
| Prednisone | 20 | $340 | $17 |
| Fluticasone Propionate | 12 | $210 | $18 |
| Zolpidem | 22 | $196 | $9 |
| Ropinirole | 11 | $177 | $16 |
| Clonazepam | 38 | $148 | $4 |
| Gabapentin | 11 | $148 | $13 |
| Trazodone | 25 | $126 | $5 |
2021: 25 drugs
| Ofev | 13 | $144,790 | $11,138 |
| Esbriet | 12 | $130,105 | $10,842 |
| Trelegy Ellipta | 95 | $91,159 | $960 |
| Breo Ellipta | 84 | $46,959 | $559 |
| Spiriva Respimat | 35 | $29,570 | $845 |
| Incruse Ellipta | 40 | $21,052 | $526 |
| Stiolto Respimat | 18 | $16,880 | $938 |
| Breztri Aerosphere | 15 | $11,562 | $771 |
| Belsomra | 15 | $10,979 | $732 |
| Advair Hfa | 12 | $9,467 | $789 |
| Wixela Inhub | 12 | $7,619 | $635 |
| Symbicort | 13 | $7,548 | $581 |
| Anoro Ellipta | 13 | $6,544 | $503 |
| Arnuity Ellipta | 15 | $5,156 | $344 |
| Lansoprazole | 12 | $3,946 | $329 |
| Budesonide-Formoterol | 12 | $3,450 | $288 |
| Albuterol Sulfate Hfa | 24 | $2,371 | $99 |
| Azelastine | 20 | $1,925 | $96 |
| Ropinirole | 32 | $715 | $22 |
| Montelukast | 69 | $643 | $9 |
| Trazodone | 35 | $270 | $8 |
| Fluticasone Propionate | 12 | $210 | $18 |
| Clonazepam | 25 | $152 | $6 |
| Prednisone | 13 | $119 | $9 |
| Zolpidem | 15 | $117 | $8 |
2020: 17 drugs
| Esbriet | 11 | $115,591 | $10,508 |
| Glassia | 14 | $105,372 | $7,527 |
| Trelegy Ellipta | 62 | $54,712 | $882 |
| Breo Ellipta | 71 | $36,860 | $519 |
| Spiriva Respimat | 55 | $31,244 | $568 |
| Incruse Ellipta | 50 | $22,675 | $453 |
| Stiolto Respimat | 20 | $14,846 | $742 |
| Symbicort | 18 | $8,654 | $481 |
| Belsomra | 14 | $8,476 | $605 |
| Arnuity Ellipta | 22 | $7,767 | $353 |
| Anoro Ellipta | 13 | $7,644 | $588 |
| Striverdi Respimat | 13 | $3,134 | $241 |
| Azelastine | 32 | $1,999 | $62 |
| Ropinirole | 37 | $640 | $17 |
| Montelukast | 41 | $612 | $15 |
| Clonazepam | 22 | $352 | $16 |
| Zolpidem | 18 | $114 | $6 |
2019: 16 drugs
| Esbriet | 12 | $121,804 | $10,150 |
| Glassia | 14 | $109,822 | $7,844 |
| Trelegy Ellipta | 42 | $37,585 | $895 |
| Breo Ellipta | 45 | $22,123 | $492 |
| Incruse Ellipta | 32 | $15,397 | $481 |
| Advair Diskus | 17 | $8,378 | $493 |
| Symbicort | 14 | $7,280 | $520 |
| Spiriva Respimat | 11 | $6,183 | $562 |
| Spiriva | 12 | $5,513 | $459 |
| Belsomra | 12 | $4,401 | $367 |
| Arnuity Ellipta | 11 | $3,027 | $275 |
| Azelastine | 14 | $1,202 | $86 |
| Montelukast | 30 | $523 | $17 |
| Ropinirole | 24 | $517 | $22 |
| Zolpidem | 23 | $246 | $11 |
| Clonazepam | 15 | $168 | $11 |
2018: 16 drugs
| Glassia | 13 | $100,991 | $7,769 |
| Advair Diskus | 27 | $19,517 | $723 |
| Breo Ellipta | 37 | $18,148 | $490 |
| Incruse Ellipta | 34 | $15,700 | $462 |
| Spiriva | 23 | $10,173 | $442 |
| Spiriva Respimat | 22 | $9,646 | $438 |
| Symbicort | 19 | $8,192 | $431 |
| Daliresp | 17 | $5,946 | $350 |
| Proair Hfa | 14 | $849 | $61 |
| Ipratropium-Albuterol | 19 | $822 | $43 |
| Ropinirole | 22 | $543 | $25 |
| Montelukast | 33 | $499 | $15 |
| Fentanyl | 13 | $328 | $25 |
| Zolpidem | 27 | $249 | $9 |
| Azithromycin | 14 | $223 | $16 |
| Diazepam | 12 | $63 | $5 |
2017: 18 drugs
| Glassia | 12 | $90,966 | $7,581 |
| Breo Ellipta | 53 | $22,606 | $427 |
| Advair Diskus | 30 | $21,904 | $730 |
| Spiriva | 32 | $17,288 | $540 |
| Symbicort | 40 | $13,756 | $344 |
| Spiriva Respimat | 19 | $11,027 | $580 |
| Incruse Ellipta | 24 | $9,753 | $406 |
| Daliresp | 23 | $7,515 | $327 |
| Advair Hfa | 12 | $5,691 | $474 |
| Ipratropium-Albuterol | 28 | $888 | $32 |
| Proair Hfa | 15 | $855 | $57 |
| Montelukast | 40 | $612 | $15 |
| Ropinirole | 33 | $463 | $14 |
| Zolpidem | 21 | $277 | $13 |
| Azithromycin | 17 | $240 | $14 |
| Clonazepam | 20 | $122 | $6 |
| Pramipexole Dihydrochloride | 13 | $116 | $9 |
| Trazodone | 13 | $54 | $4 |
2016: 20 drugs
| Glassia | 13 | $99,304 | $7,639 |
| Advair Diskus | 57 | $30,800 | $540 |
| Spiriva | 64 | $26,417 | $413 |
| Breo Ellipta | 57 | $19,927 | $350 |
| Symbicort | 46 | $14,119 | $307 |
| Spiriva Respimat | 21 | $8,507 | $405 |
| Advair Hfa | 21 | $8,464 | $403 |
| Daliresp | 23 | $6,832 | $297 |
| Budesonide | 32 | $4,224 | $132 |
| Ipratropium-Albuterol | 23 | $828 | $36 |
| Montelukast | 39 | $668 | $17 |
| Proair Hfa | 11 | $595 | $54 |
| Zolpidem | 29 | $347 | $12 |
| Ropinirole | 28 | $332 | $12 |
| Azithromycin | 22 | $313 | $14 |
| Fluticasone Propionate | 11 | $167 | $15 |
| Pramipexole Dihydrochloride | 14 | $152 | $11 |
| Prednisone | 14 | $147 | $11 |
| Clonazepam | 17 | $102 | $6 |
| Furosemide | 12 | $50 | $4 |
2015: 20 drugs
| Glassia | 12 | $90,801 | $7,567 |
| Spiriva | 106 | $43,311 | $409 |
| Advair Diskus | 64 | $27,987 | $437 |
| Symbicort | 57 | $16,580 | $291 |
| Advair Hfa | 18 | $6,932 | $385 |
| Breo Ellipta | 23 | $6,382 | $277 |
| Daliresp | 19 | $4,986 | $262 |
| Nasonex | 11 | $2,315 | $210 |
| Montelukast | 60 | $1,959 | $33 |
| Modafinil | 11 | $1,820 | $165 |
| Ventolin Hfa | 25 | $1,455 | $58 |
| Azithromycin | 28 | $705 | $25 |
| Proair Hfa | 13 | $661 | $51 |
| Azelastine | 11 | $523 | $48 |
| Ropinirole | 26 | $227 | $9 |
| Morphine Sulfate | 11 | $192 | $17 |
| Hydrocodone-Acetaminophen | 14 | $186 | $13 |
| Pramipexole Dihydrochloride | 14 | $175 | $13 |
| Zolpidem | 12 | $170 | $14 |
| Clonazepam | 14 | $49 | $3 |
2014: 15 drugs
| Glassia | 13 | $95,735 | $7,364 |
| Spiriva | 125 | $48,200 | $386 |
| Advair Diskus | 72 | $32,536 | $452 |
| Symbicort | 36 | $11,583 | $322 |
| Modafinil | 13 | $4,973 | $383 |
| Daliresp | 14 | $3,264 | $233 |
| Xopenex Hfa | 16 | $1,384 | $86 |
| Montelukast | 34 | $812 | $24 |
| Azithromycin | 21 | $697 | $33 |
| Fluticasone Propionate | 17 | $437 | $26 |
| Clonazepam | 24 | $330 | $14 |
| Pramipexole Dihydrochloride | 16 | $306 | $19 |
| Prednisone | 15 | $176 | $12 |
| Methadone | 12 | $141 | $12 |
| Zolpidem | 15 | $88 | $6 |
2013: 14 drugs
| Advair Diskus | 84 | $30,578 | $364 |
| Spiriva | 77 | $28,787 | $374 |
| Symbicort | 17 | $6,128 | $360 |
| Daliresp | 12 | $2,428 | $202 |
| Xopenex Hfa | 19 | $1,863 | $98 |
| Montelukast | 11 | $924 | $84 |
| Proair Hfa | 15 | $896 | $60 |
| Fluticasone Propionate | 14 | $792 | $57 |
| Pramipexole Dihydrochloride | 14 | $550 | $39 |
| Azithromycin | 12 | $404 | $34 |
| Omeprazole | 12 | $387 | $32 |
| Clonazepam | 23 | $369 | $16 |
| Zolpidem | 24 | $127 | $5 |
| Prednisone | 11 | $82 | $7 |
Money from drug and device companies
$3,061 in 2025
| 2025 | 22 | 120 | None | $3,061 |
| 2024 | 24 | 131 | None | $3,021 |
| 2023 | 23 | 144 | None | $3,012 |
| 2022 | 21 | 145 | None | $3,036 |
| 2021 | 18 | 90 | None | $1,780 |
| 2020 | 8 | 12 | None | $295 |
| 2019 | 10 | 28 | $150 | $474 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boehringer Ingelheim Pharmaceuticals | Ofev | $454 | 17 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $453 | 19 payments
|
| Inspire Medical Systems | Inspire | $430 | 11 payments
|
| Jazz Pharmaceuticals | Xywav | $242 | 7 payments
|
| Grifols USA | Prolastin-C Liquid | $163 | 5 payments
|
| GlaxoSmithKline | Nucala | $156 | 11 payments
|
See all 115 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-23 | Jascayd | $27 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-17 | Jascayd | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-16 | Fasenra | $20 |
| Amgen | Meals · 2025-12-09 | Tezspire | $28 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-08 | Jascayd | $31 |
| Inspire Medical Systems | Meals · 2025-12-05 | Inspire | $161 |
| Insmed | Meals · 2025-11-26 | Arikayce | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-26 | Jascayd | $23 |
| Philips North America | Meals · 2025-11-18 | Vest Therapy Und | $25 |
| Philips North America | Meals · 2025-11-17 | Full Face Masks - Over the Head | $19 |
| Inspire Medical Systems | Meals · 2025-11-12 | Inspire | $9 |
| Amgen | Meals · 2025-11-11 | Tezspire | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-10 | Jascayd | $27 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-03 | Jascayd | $12 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-31 | Jascayd | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-22 | Tezspire | $34 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-20 | Jascayd | $32 |
| Grifols USA | Meals · 2025-10-18 | Prolastin-C Liquid | $28 |
| Insmed | Education · 2025-10-17 | Brinsupri | $17 |
| Insmed | Meals · 2025-10-15 | Arikayce | $21 |
| United Therapeutics | Meals · 2025-10-15 | Tyvaso | $30 |
| Philips North America | Meals · 2025-10-07 | Vest Therapy Und | $19 |
| GlaxoSmithKline | Meals · 2025-10-02 | Nucala | $5 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-10-01 | Ofev | $31 |
| Fisher & Paykel Healthcare | Meals · 2025-09-30 | Fisher & Paykel Healthcare | $27 |
| Philips North America | Meals · 2025-09-26 | Vest Therapy Und | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-25 | Breztri | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-23 | None | $29 |
| Lilly USA | Meals · 2025-09-22 | Zepbound | $21 |
| Jazz Pharmaceuticals | Meals · 2025-09-20 | Xywav | $27 |
| Insmed | Meals · 2025-08-30 | Arikayce | $32 |
| Philips North America | Meals · 2025-08-27 | Vest Therapy Und | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-20 | Breztri | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-20 | Tezspire | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-20 | Breztri | $28 |
| Harmony Biosciences | Meals · 2025-08-15 | Wakix | $34 |
| Grifols USA | Meals · 2025-08-14 | Prolastin-C Liquid | $37 |
| Genzyme | Meals · 2025-08-12 | Dupixent | $28 |
| Sanofi-Aventis U.S. | Education · 2025-08-05 | Dupixent | $100 |
| Inspire Medical Systems | Meals · 2025-07-30 | Inspire | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-28 | Ofev | $26 |
| Vifor Pharma | Meals · 2025-07-25 | Zemaira | $25 |
| Grifols USA | Meals · 2025-07-23 | Prolastin-C Liquid | $37 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-22 | Breztri | $20 |
| United Therapeutics | Meals · 2025-07-16 | Tyvaso | $21 |
| Lilly USA | Meals · 2025-07-15 | None | $16 |
| GlaxoSmithKline | Meals · 2025-07-15 | Trelegy Ellipta | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-15 | Breztri | $14 |
| Jazz Pharmaceuticals | Education · 2025-07-08 | Xywav | $70 |
| Jazz Pharmaceuticals | Education · 2025-07-08 | Xywav | $55 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-02 | Tezspire | $23 |
| Inspire Medical Systems | Meals · 2025-06-30 | Inspire | $7 |
| Grifols USA | Meals · 2025-06-28 | Prolastin-C Liquid | $36 |
| Inspire Medical Systems | Meals · 2025-06-25 | Inspire | $22 |
| Merck Sharp & Dohme | Meals · 2025-06-24 | Zerbaxa | $22 |
| Avadel CNS Pharmaceuticals | Meals · 2025-06-23 | Lumryz | $28 |
| Jazz Pharmaceuticals | Meals · 2025-06-19 | Xywav | $20 |
| GlaxoSmithKline | Meals · 2025-06-17 | Nucala | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-13 | None | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-12 | Breztri | $26 |
| Amgen | Meals · 2025-06-10 | Tezspire | $31 |
| GlaxoSmithKline | Meals · 2025-06-02 | Nucala | $3 |
| Lilly USA | Meals · 2025-05-30 | Mounjaro | $21 |
| Lilly USA | Meals · 2025-05-30 | Mounjaro | $0 |
| Jazz Pharmaceuticals | Meals · 2025-05-30 | Xywav | $10 |
| Inspire Medical Systems | Meals · 2025-05-30 | Inspire | $75 |
| Jazz Pharmaceuticals | Meals · 2025-05-24 | Xywav | $26 |
| Inspire Medical Systems | Meals · 2025-05-20 | Inspire | $11 |
| GlaxoSmithKline | Meals · 2025-05-14 | Nucala | $3 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-14 | Airsupra | $22 |
| GlaxoSmithKline | Meals · 2025-05-07 | Nucala | $3 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-07 | Ofev | $28 |
| Inspire Medical Systems | Meals · 2025-05-02 | Inspire | $37 |
| Resmed | Meals · 2025-04-30 | Airsense | $17 |
| Inspire Medical Systems | Meals · 2025-04-19 | Inspire | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-16 | Fasenra | $18 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-15 | Ofev | $34 |
| Jazz Pharmaceuticals | Meals · 2025-04-15 | Xywav | $34 |
| Fisher & Paykel Healthcare | Meals · 2025-04-11 | Fisher & Paykel Healthcare | $21 |
| Merck Sharp & Dohme | Meals · 2025-04-09 | Zerbaxa | $22 |
| Genzyme | Meals · 2025-04-08 | Dupixent | $30 |
| Lilly USA | Meals · 2025-04-07 | Zepbound | $18 |
| Merck Sharp & Dohme | Meals · 2025-04-04 | Zerbaxa | $21 |
| United Therapeutics | Meals · 2025-04-02 | Tyvaso | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-01 | Tezspire | $30 |
| Philips North America | Meals · 2025-04-01 | Vest Therapy Und | $20 |
| Insmed | Meals · 2025-03-28 | Arikayce | $28 |
| Inspire Medical Systems | Meals · 2025-03-28 | Inspire | $43 |
| Inspire Medical Systems | Meals · 2025-03-26 | Inspire | $14 |
| GlaxoSmithKline | Meals · 2025-03-20 | Nucala | $3 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-19 | Ofev | $28 |
| Harmony Biosciences | Meals · 2025-03-18 | Wakix | $33 |
| GlaxoSmithKline | Meals · 2025-03-17 | Trelegy Ellipta | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-12 | Airsupra | $17 |
| Grifols USA | Meals · 2025-03-11 | Prolastin-C Liquid | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-05 | Fasenra | $19 |
| GlaxoSmithKline | Meals · 2025-03-04 | Nucala | $21 |
| Lilly USA | Meals · 2025-03-03 | Zepbound | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-26 | Ofev | $31 |
| Verona Pharma | Meals · 2025-02-24 | Ohtuvayre | $33 |
| Itamar Medical | Meals · 2025-02-21 | Watchpatone | $24 |
| Avadel CNS Pharmaceuticals | Meals · 2025-02-19 | Lumryz | $39 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-12 | Airsupra | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-12 | Airsupra | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-11 | Ofev | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-10 | Fasenra | $19 |
| Electromed | Meals · 2025-02-05 | Smartvest | $18 |
| United Therapeutics | Meals · 2025-02-04 | Tyvaso | $30 |
| Avadel CNS Pharmaceuticals | Meals · 2025-01-28 | Lumryz | $32 |
| GlaxoSmithKline | Meals · 2025-01-26 | Trelegy Ellipta | $22 |
| Harmony Biosciences | Meals · 2025-01-21 | Wakix | $34 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-15 | Ofev | $28 |
| Merck Sharp & Dohme | Meals · 2025-01-14 | Zerbaxa | $23 |
| GlaxoSmithKline | Meals · 2025-01-13 | Nucala | $28 |
| Fisher & Paykel Healthcare | Meals · 2025-01-09 | Fisher & Paykel Healthcare | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,021
| GlaxoSmithKline | Trelegy Ellipta | $499 | 25 payments
|
| Jazz Pharmaceuticals | Xywav | $428 | 9 payments
|
| AstraZeneca Pharmaceuticals LP | Airsupra | $249 | 12 payments
|
| Baxter Healthcare | Hillrom - Vest System Model 105 Home Care | $191 | 11 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $187 | 13 payments
|
| Harmony Biosciences | Wakix | $179 | 4 payments
|
| Inspire Medical Systems | Inspire | $172 | 6 payments
|
| Vanda Pharmaceuticals | Hetlioz | $136 | 5 payments
|
| Genzyme | Dupixent | $129 | 6 payments
|
| Merck Sharp & Dohme | Zerbaxa | $117 | 5 payments
|
| Fisher & Paykel Healthcare | Fisher & Paykel Healthcare | $110 | 3 payments
|
| Avadel CNS Pharmaceuticals | Lumryz | $92 | 4 payments
|
| Sanofi-Aventis U.S. | Dupixent | $79 | 1 payment
|
| Pulmonx | Chartis Catheter | $75 | 4 payments
|
| Insmed | Arikayce | $65 | 3 payments
|
| United Therapeutics | Tyvaso | $58 | 3 payments
|
| Grifols USA | Prolastin-C Liquid | $52 | 2 payments
|
| Resmed | Airsense | $45 | 2 payments
|
| Electromed | Smartvest | $40 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $31 | 1 payment
|
| Axsome Therapeutics | Sunosi | $29 | 1 payment
|
| La Jolla Pharmaceutical | Giapreza | $27 | 1 payment
|
| Philips North America | (Di5) Full Face Masks - Over the Head | $17 | 1 payment
|
| Vifor Pharma | Veltassa | $14 | 1 payment
|
2023: $3,012
| GlaxoSmithKline | Trelegy Ellipta | $489 | 23 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $408 | 14 payments
|
| AstraZeneca Pharmaceuticals LP | Airsupra | $293 | 13 payments
|
| Vanda Pharmaceuticals | Hetlioz | $205 | 9 payments
|
| Harmony Biosciences | Wakix | $200 | 7 payments
|
| Baxter Healthcare | Hillrom - Vest System Model 105 Home Care | $199 | 17 payments
|
| Genzyme | Dupixent | $192 | 9 payments
|
| Merck Sharp & Dohme | Belsomra | $168 | 8 payments
|
| Grifols USA | Prolastin-C Liquid | $106 | 5 payments
|
| Insmed | Arikayce | $96 | 4 payments
|
| Sanofi-Aventis U.S. | Dupixent | $80 | 1 payment
|
| Amgen | Tezspire | $80 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $78 | 3 payments
|
| United Therapeutics | Tyvaso | $67 | 3 payments
|
| Electromed | Smartvest | $65 | 5 payments
|
| Jazz Pharmaceuticals | Xywav | $58 | 3 payments
|
| Axsome Therapeutics | Sunosi | $54 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $50 | 3 payments
|
| Inspire Medical Systems | Inspire | $42 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Adempas | $26 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $26 | 1 payment
|
| La Jolla Pharmaceutical | Giapreza | $20 | 1 payment
|
| Itamar Medical | Watchpatone | $7 | 1 payment
|
2022: $3,036
| GlaxoSmithKline | Trelegy Ellipta | $637 | 33 payments
|
| Boehringer Ingelheim Pharmaceuticals | Ofev | $426 | 22 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $354 | 16 payments
|
| Harmony Biosciences | Wakix | $277 | 7 payments
|
| Actelion Pharmaceuticals US | Opsumit | $250 | 5 payments
|
| Genzyme | Dupixent | $227 | 12 payments
|
| Baxter Healthcare | Hillrom - Vest System Model 105 Home Care | $202 | 13 payments
|
| Janssen Pharmaceuticals | Xarelto | $69 | 3 payments
|
| Abbvie | Avycaz | $68 | 4 payments
|
| Teva Pharmaceuticals USA | Airduo Digihaler | $66 | 4 payments
|
| Philips Electronics North America | (1944) Pri Cpap | $63 | 2 payments
|
| Jazz Pharmaceuticals | Xywav | $56 | 2 payments
|
| Merck Sharp & Dohme | Belsomra | $55 | 3 payments
|
| Electromed | Smartvest | $48 | 3 payments
|
| Genentech USA | Esbriet | $47 | 2 payments
|
| United Therapeutics | Tyvaso | $46 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Adempas | $45 | 2 payments
|
| Fisher & Paykel Healthcare | Fisher & Paykel Healthcare | $42 | 1 payment
|
| Mayne Pharma | None | $22 | 1 payment
|
| Amgen | Tezspire | $20 | 1 payment
|
| Resmed | Air 11 | $16 | 1 payment
|
2021: $1,780
| Boehringer Ingelheim Pharmaceuticals | Stiolto Respimat | $357 | 18 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $315 | 19 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $207 | 11 payments
|
| Amgen | None | $177 | 3 payments
|
| Advanced Respiratory | The Vest System Model 105 Home Care | $150 | 11 payments
|
| Acerta Pharma | None | $125 | 1 payment
|
| Resmed | Aircurve | $71 | 4 payments
|
| Pulmonx | Chartis Catheter | $59 | 3 payments
|
| Philips Electronics North America | (8874) Incourage | $52 | 2 payments
|
| Harmony Biosciences | Wakix | $47 | 1 payment
|
| Genentech USA | Xolair | $43 | 2 payments
|
| Jazz Pharmaceuticals | Sunosi | $37 | 2 payments
|
| Eisai | Dayvigo | $37 | 2 payments
|
| Pfizer | Eliquis | $26 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Glassia | $24 | 1 payment
|
| Genzyme | Dupixent | $21 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $16 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $15 | 1 payment
|
2020: $295
| AstraZeneca Pharmaceuticals LP | Symbicort | $59 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $52 | 2 payments
|
| Jazz Pharmaceuticals | Sunosi | $45 | 1 payment
|
| Merck Sharp & Dohme | Belsomra | $41 | 2 payments
|
| GlaxoSmithKline | Anoro Ellipta | $33 | 1 payment
|
| Advanced Respiratory | The Vest System Model 105 Home Care | $24 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $20 | 1 payment
|
| Genentech USA | Esbriet | $20 | 1 payment
|
2019: $474
| Comsort | Pneumovax 23 | $150 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Symbicort | $123 | 7 payments
|
| Sunovion Pharmaceuticals | Lonhala Magnair | $43 | 5 payments
|
| Resmed | Airfit | $39 | 1 payment
|
| GlaxoSmithKline | Anoro | $23 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $22 | 1 payment
|
| Genentech USA | Esbriet | $21 | 1 payment
|
| Teva Pharmaceuticals USA | Cinqair | $20 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $19 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $13 | 1 payment
|
Checkups this office reported
17 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 90.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Appropriate Treatment for Upper Respiratory Infection (URI)As Medicare defines this measure | 100% | 26 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 90%That's most of the people this applied to. | 745 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 69%That's more than half. | 495 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 4%That's few of the people this applied to. Better on this measure. | 75 |
| Breast cancer screeningEligible women who got a mammogram | 90%That's most of the people this applied to. | 343 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 68%That's more than half. | 305 |
| Checked for fall riskOlder patients screened for fall risk | 57%That's more than half. | 700 |
| Colon cancer screeningEligible adults who got a colon cancer test | 76%That's most of the people this applied to. | 740 |
See the other 9 measures
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 45%That's less than half. | 862 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 37%That's less than half. | 132 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 18%That's few of the people this applied to. Better on this measure. | 132 |
| HIV screeningEligible patients who were screened for HIV | 32%That's less than half. | 667 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 2,520 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 516 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 99%That's most of the people this applied to. | 157 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 81%That's most of the people this applied to. | 544 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 52%That's more than half. | 1,302 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- Improved the patient portal
- Lets patients read their visit notes
- Reports cases to public health electronically
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
- Exempt from immunization registry reporting
Professional record
- NPI
- 1881643831
- Licence
- CA C51289California C51289: Current · expires 2027-02-28
- Group
- Bass Medical Group
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00C512890
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RS0012X (207RS0012X)
- Mailing address
- 2637 Shadelands Dr, Walnut Creek, CA, 94598
- NPI first listed
- 2006-05-08
- NPI last updated
- 2024-12-02
- NPI record certified
- 2024-12-02
This is when the NPI record was last certified, not a medical board exam.